IRD supply chain intelligence for Opus Genetics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| OPCM-SA-LLC | OPCM-SA-LLC | 92% | As previously disclosed, on April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agre… |
| MASSACHUSETTS-EYE-AND-EAR-INFIRMARY | MASSACHUSETTS-EYE-AND-EAR-INFIRMARY | 90% | In return for these rights, the Company is obligated to make certain development milestone payments and royalty payments on future sales of such products. |
| PENN-AND-UF | PENN-AND-UF | 90% | In return for these rights, the Company is obligated to make certain development milestone payments and royalty payments on future sales of such products. |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: Reciprocal relationship from MYGN gra… |
| MYGN | Myriad Genetics, Inc. | 72% | patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation proceedings may be costly or time-consu… |
| OCUL | Ocular Therapeutix, Inc. | 72% | line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop gen… |
| OCUL | Ocular Therapeutix, Inc. | 72% | Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD graph: line products, our business will be materially harmed. • Others may discover, develop, or commercialize products simil… |
| ORANY | ORANY | 72% | place. A request for proposal process, to include small scale process development, technical transfer, and analytical method development, to identify a manufacturing partner is being conducted. The o… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IRD graph: place. A request for proposal process, to include small scale process development, technical transfer, and analytical… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| VIATRIS | VIATRIS | 92% | The Company will be eligible to receive potential additional payments of up to $130 million upon achieving certain specified regulatory or net sales milestones, with the first milestone payment of $1… |
| MYGN | Myriad Genetics, Inc. | 72% | patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation proceedings may be costly or time-consu… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review… |
| OCUL | Ocular Therapeutix, Inc. | 72% | Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD graph: line products, our business will be materially harmed. • Others may discover, develop, or commercialize products simil… |
| OCUL | Ocular Therapeutix, Inc. | 72% | line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop gen… |
| ORANY | ORANY | 72% | utics (LNZ100 - 1.75% Aceclidine) and AbbVie (VUITY® (pilocarpine hydrochloride ophthalmic solution) - 1.25%). We are not aware of direct competition for the treatment of DLD following keratorefracti… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IRD graph: utics (LNZ100 - 1.75% Aceclidine) and AbbVie (VUITY® (pilocarpine hydrochloride ophthalmic solution) - 1.25%). We are… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IRD-DEBT | Debt stack $1.1M | 90% | Market cache reports total debt of $1.1M. |
| IRD-DEBT-10355 | Warrants outstanding: 9.6 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| IRD-DEBT-10356 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IRD-OWNER-CALIGAN-PARTNERS-LP | Caligan Partners LP | 90% | 13F overlay lists Caligan Partners LP as top holder; 79 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ATYR | aTyr Pharma, Inc. | 100.00 | 2 | |
| TEM | Tempus AI, Inc. | 100.00 | 2 | |
| TECX | Tectonic Therapeutic, Inc. | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 | |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 | |
| GH | Guardant Health, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 | |
| BIAF | bioAffinity Technologies, Inc. | 100.00 | 2 | |
| IMNM | Immunome, Inc. | 100.00 | 2 | |
| TPST | Tempest Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| KDK | Kodiak AI, Inc. | 100.00 | 2 |